Evelo Biosciences now has $85 million to spend on its pipeline of drugs that target the human microbiome. The Cambridge, MA-based biotech priced its initial public offering of 5.3 million shares at $16, right at the midpoint of the $15 to $17 range it had previously set. Evelo’s shares are expected to begin trading on […]
Original Article: Evelo IPO Raises $85M for Microbiome Drugs in Inflammation, Cancer